These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 21456039)

  • 1. Double-blind randomized parallel-group clinical trial of efficacy of the combination fluoxetine plus modafinil versus fluoxetine plus placebo in the treatment of major depression.
    Abolfazli R; Hosseini M; Ghanizadeh A; Ghaleiha A; Tabrizi M; Raznahan M; Golalizadeh M; Akhondzadeh S
    Depress Anxiety; 2011 Apr; 28(4):297-302. PubMed ID: 21456039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Residual symptoms after remission of major depressive disorder with fluoxetine and risk of relapse.
    Iovieno N; van Nieuwenhuizen A; Clain A; Baer L; Nierenberg AA
    Depress Anxiety; 2011 Feb; 28(2):137-44. PubMed ID: 21284066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder.
    Garakani A; Martinez JM; Marcus S; Weaver J; Rickels K; Fava M; Hirschowitz J
    Int Clin Psychopharmacol; 2008 Sep; 23(5):269-75. PubMed ID: 18703936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Morning fluoxetine plus evening mianserin versus morning fluoxetine plus evening placebo in the acute treatment of major depression.
    Dam J; Ryde L; Svejsø J; Lauge N; Lauritsen B; Bech P
    Pharmacopsychiatry; 1998 Mar; 31(2):48-54. PubMed ID: 9562208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hopelessness as a predictor of non-response to fluoxetine in major depressive disorder.
    Papakostas GI; Petersen T; Homberger CH; Green CH; Smith J; Alpert JE; Fava M
    Ann Clin Psychiatry; 2007; 19(1):5-8. PubMed ID: 17453655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluoxetine versus trimipramine in the treatment of depression in geriatric patients.
    Wehmeier PM; Kluge M; Maras A; Riemann D; Berger M; Kohnen R; Dittmann RW; Gattaz WF
    Pharmacopsychiatry; 2005 Jan; 38(1):13-6. PubMed ID: 15706460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modafinil for the treatment of hypersomnia associated with myotonic muscular dystrophy in adults: a multicenter, prospective, randomized, double-blind, placebo-controlled, 4-week trial.
    Orlikowski D; Chevret S; Quera-Salva MA; Laforêt P; Lofaso F; Verschueren A; Pouget J; Eymard B; Annane D
    Clin Ther; 2009 Aug; 31(8):1765-73. PubMed ID: 19808135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preliminary randomized double-blind placebo-controlled trial of tryptophan combined with fluoxetine to treat major depressive disorder: antidepressant and hypnotic effects.
    Levitan RD; Shen JH; Jindal R; Driver HS; Kennedy SH; Shapiro CM
    J Psychiatry Neurosci; 2000 Sep; 25(4):337-46. PubMed ID: 11022398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Moclobemide versus fluoxetine in the treatment of major depressive disorder in adults.
    Lapierre YD; Joffe R; McKenna K; Bland R; Kennedy S; Ingram P; Reesal R; Rickhi BG; Beauclair L; Chouinard G; Annable L
    J Psychiatry Neurosci; 1997 Mar; 22(2):118-26. PubMed ID: 9074306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral scopolamine augmentation in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled study.
    Khajavi D; Farokhnia M; Modabbernia A; Ashrafi M; Abbasi SH; Tabrizi M; Akhondzadeh S
    J Clin Psychiatry; 2012 Nov; 73(11):1428-33. PubMed ID: 23146150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Psychic and somatic anxiety symptoms as predictors of response to fluoxetine in major depressive disorder.
    Papakostas GI; McGrath P; Stewart J; Charles D; Chen Y; Mischoulon D; Dording C; Fava M
    Psychiatry Res; 2008 Oct; 161(1):116-20. PubMed ID: 18755514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of depression and anxiety in infertile women: cognitive behavioral therapy versus fluoxetine.
    Faramarzi M; Alipor A; Esmaelzadeh S; Kheirkhah F; Poladi K; Pash H
    J Affect Disord; 2008 May; 108(1-2):159-64. PubMed ID: 17936366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early improvements in anxiety, depression, and anger/hostility symptoms and response to antidepressant treatment.
    Farabaugh A; Sonawalla S; Johnson DP; Witte J; Papakostas GI; Goodness T; Clain A; Baer L; Mischoulon D; Fava M; Harley R
    Ann Clin Psychiatry; 2010 Aug; 22(3):166-71. PubMed ID: 20680189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression.
    Patkar AA; Masand PS; Pae CU; Peindl K; Hooper-Wood C; Mannelli P; Ciccone P
    J Clin Psychopharmacol; 2006 Dec; 26(6):653-6. PubMed ID: 17110825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hydro-alcoholic extract of Crocus sativus L. versus fluoxetine in the treatment of mild to moderate depression: a double-blind, randomized pilot trial.
    Noorbala AA; Akhondzadeh S; Tahmacebi-Pour N; Jamshidi AH
    J Ethnopharmacol; 2005 Feb; 97(2):281-4. PubMed ID: 15707766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of fluoxetine and doxepin in treatment of melancholia in depressed patients.
    Sandor P; Baker B; Irvine J; Dorian P; McKessok D; Mendlowitz S
    Depress Anxiety; 1998; 7(2):69-72. PubMed ID: 9614594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sexual functioning in patients with recurrent major depressive disorder enrolled in the PREVENT study.
    Gelenberg AJ; Dunner DL; Rothschild AJ; Pedersen R; Dorries KM; Ninan PT
    J Nerv Ment Dis; 2013 Apr; 201(4):266-73. PubMed ID: 23538970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A double-blind, placebo-controlled treatment trial of citalopram for major depressive disorder in older patients with heart failure: the relevance of the placebo effect and psychological symptoms.
    Fraguas R; da Silva Telles RM; Alves TC; Andrei AM; Rays J; Iosifescu DV; Wajngarten M
    Contemp Clin Trials; 2009 May; 30(3):205-11. PubMed ID: 19470312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modafinil for atypical depression: effects of open-label and double-blind discontinuation treatment.
    Vaishnavi S; Gadde K; Alamy S; Zhang W; Connor K; Davidson JR
    J Clin Psychopharmacol; 2006 Aug; 26(4):373-8. PubMed ID: 16855454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using psychostimulants for treating residual symptoms in major depression.
    Berlim MT; Turecki MG
    J Psychiatry Neurosci; 2007 Jul; 32(4):304. PubMed ID: 17653297
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.